Atara Biotherapeutics, Inc. to Present at the Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Gad Soffer, the company's Chief Operating Officer, will present at the 2015 Needham Healthcare Conference on Tuesday, April 14, 2015 at 5:00 pm EDT in New York City.
The live audio webcast of the company presentation will be accessible from the company's investor relations website at http://investors.atarabio.com/events.cfm. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. An archive of the webcast will be available for at least 30 days following the presentation.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases. Atara's lead programs target myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. In September 2014, Atara Biotherapeutics entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center (MSK), under which it has the right to license (pursuant to a negotiated form of license agreement) the exclusive, worldwide rights to three clinical stage T-cell programs, including Epstein-Barr virus-targeted cytotoxic T lymphocytes, which recently received breakthrough therapy designation from the Food and Drug Administration, as well as other T-cell programs that are discovered or developed by MSK pursuant to sponsored research funded by the company.
CONTACT: INVESTOR CONTACT:
Tina Gullotta, Atara Biotherapeutics, Inc.
650-741-1613
tgullotta@atarabio.com
MEDIA CONTACT:
Susan Heins, Pure Communications, Inc.
864-286-9597
susan@purecommunicationsinc.com
Source: Atara Biotherapeutics
Released April 9, 2015